DTSQ.NASDAQDt Cloud Star Acquisition CORP

425: DT Cloud Star to Merge with Biotech Firm PrimeGen US

Sentiment:

Business Combination Agreement 6 February 2026 4:32 PM

📋All filings for Dt Cloud Star Acquisition CORP

DT Cloud Star Acquisition Corporation has entered into a definitive business combination agreement to merge with PrimeGen US, Inc., a biotechnology company focused on stem cell therapies, valuing PrimeGen at approximately $1.49 billion.

Delay expectedThe Business Combination Agreement specifies an 'Outside Date' of October 26, 2026, for the closing.This 'Outside Date' may be extended by three months if mutually agreed upon by Parent and Company, provided Parent obtains the necessary shareholder approval for such an extension.

Capital raiseThe remaining funds in the Trust Account, along with the net proceeds of a 'Closing PIPE' (private placement of equity securities), will be used to pay Parent Transaction Expenses and for the working capital and general corporate purposes of the Surviving Corporation.The Company is permitted to conduct private offerings of equity securities not to exceed, in the aggregate, 20% of its issued and outstanding common stock (on a fully diluted basis) as of the agreement date, prior to the closing.

Summary

DT Cloud Star Acquisition Corporation (DTCS), a SPAC, has entered into a Business Combination Agreement (BCA) with PrimeGen US, Inc., a biotechnology company specializing in stem cell therapies.
The transaction involves a two-step merger: DTCS will first merge into DTSQ Purchaser Inc. (Purchaser), which will then merge with PrimeGen US, Inc., with PrimeGen surviving as a wholly-owned subsidiary of Purchaser.
The aggregate value of PrimeGen US, Inc. for the merger consideration is set at $1,489,800,000.
Existing DTCS Ordinary Shares will convert into Purchaser Class A Common Stock, and DTCS Rights will convert into Purchaser rights (entitling holders to 1/9th of one Class A Common Stock).
Non-Redemption Warrants, totaling 1,931,900 shares of Purchaser Class A Common Stock with an exercise price of $2.00 per share, will be issued to non-redeeming public shareholders and other Parent Ordinary Share holders.
PrimeGen's Class A and Class B Common Stock will convert into Purchaser Class A and Class B Common Stock, respectively.
The transaction is supported by Company Support Agreements from significant PrimeGen stockholders (representing 87.40% of outstanding shares) and Insider Support Agreements from DTCS's sponsor and officers/directors.
A new equity incentive plan, providing for awards equal to 15% of the aggregate Purchaser Common Stock immediately after closing, will be adopted.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it outlines a clear path for PrimeGen US, Inc. to become a publicly traded entity, potentially unlocking significant capital for its promising stem cell therapy research. The strong insider support and detailed governance structure are favorable, though the inherent risks of biotech development and SPAC redemptions warrant caution.

Positives

A definitive agreement for a business combination has been reached, providing a clear path for PrimeGen US, Inc. to become a publicly traded entity.
PrimeGen US, Inc. is valued at a substantial $1,489,800,000, reflecting confidence in its biotechnology focus on life-saving stem cell therapies.
Strong commitment from existing stakeholders is evident, with Significant Company Holders (owning 87.40% of PrimeGen's capital stock) and DTCS Insiders agreeing to vote in favor of the merger and adhere to lock-up provisions.
The establishment of a new equity incentive plan, reserving 15% of post-closing Purchaser Common Stock, can incentivize and retain key talent for the combined entity.
PrimeGen has received an FDA reference number for a pre-IND meeting regarding its PGSXC-L1A cell therapy product candidate for Acute Alcoholic Hepatitis, indicating progress in its R&D pipeline.

Negatives

No specific financial projections, revenue, or profitability metrics for PrimeGen US, Inc. are provided, limiting a detailed financial assessment of the target company.
The transaction is subject to potential 'SEC SPAC Accounting Changes' which could lead to restatements of historical financial information.
The success of the combined entity is highly dependent on PrimeGen's ability to execute its R&D and commercialization plans for stem cell therapies, a sector known for high risk and long development cycles.
The SPAC structure introduces redemption risk, where public shareholders may elect to redeem their shares, potentially reducing the cash available to the combined company.

Risks

The proposed Business Combination may not be completed in a timely manner or at all, which could adversely affect the price of DTCS's securities.
Failure to satisfy the conditions to the consummation of the proposed Business Combination, including shareholder approvals, governmental approvals, and Nasdaq listing, poses a significant risk.
Redemptions by DTCS's public shareholders could exceed anticipated levels, impacting the capital available to the combined company.
The combined company may fail to meet Nasdaq initial listing standards.
The proposed Business Combination could disrupt PrimeGen's current plans and operations, affecting business relationships and operating results.
Potential legal proceedings may be instituted against DTCS, Purchaser, Merger Sub, or PrimeGen related to the BCA or the proposed Business Combination.
Changes in the markets in which PrimeGen competes, including competitive landscape, technology evolution, or regulatory changes, could adversely affect the business.
The combined company may be unable to execute its growth strategies, including commercialization and development plans.
Risks related to supply chain disruptions could impact operations.
The combined company may not be able to develop and maintain effective internal controls.
Costs related to the proposed Business Combination may exceed anticipated levels, and the anticipated benefits or estimated pro forma results may not be realized.
Inability to achieve successful results or obtain licensing of third-party intellectual property rights for future discovery and development of PrimeGen's projects.
Failure to commercialize products and achieve market acceptance of such products.
PrimeGen may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.
The post-combination Purchaser may experience difficulties in managing its growth and expanding operations.
Risks of product liability or regulatory lawsuits or proceedings relating to PrimeGen's business.
Risks associated with intellectual property protection, including the inability to secure or protect its intellectual property.

Future Outlook

The combined company anticipates leveraging the merger to advance PrimeGen's research and development of life-saving stem cell therapies. PrimeGen has already secured an FDA reference number for a pre-IND meeting concerning its PGSXC-L1A cell therapy product candidate for Acute Alcoholic Hepatitis, indicating a clear development path. The new equity incentive plan is designed to attract and retain talent, supporting future growth strategies and commercialization efforts. The success hinges on navigating clinical trials, regulatory approvals, and market acceptance in the dynamic biotechnology sector.

Management Comments

The boards of directors of the Parent, the Purchaser, Merger Sub and the Company have each determined that the Mergers are fair, advisable and in the best interests of their respective companies and stockholders.

Industry Context

StockSavvy.ai notes that the merger of a Special Purpose Acquisition Company (SPAC) with a biotechnology firm like PrimeGen US, Inc., which is focused on stem cell therapies, is a prominent trend in capital markets. This strategy offers private biotech companies a faster route to public listing and access to significant capital, crucial for funding extensive research and development, particularly for costly clinical trials and eventual commercialization in the high-potential, yet high-risk, cell therapy sector. PrimeGen's specific focus on 'life-saving stem cell therapies' and its progress with an FDA pre-IND meeting for Acute Alcoholic Hepatitis positions it within a competitive but potentially lucrative segment of the biotech industry.

Comparison to Industry Standards

NA (The filing does not provide specific comparable companies, projects, or results to benchmark PrimeGen's performance or valuation against industry standards.)

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Officers and Directors of Redomestication Merger Surviving Corporation	Current Parent officers and directors	Current Parent officers and directors	Redomestication Merger Effective Time	Continuity post-redomestication
Executive Officers of Purchaser (post-Closing)	Current Company executive officers	Current Company executive officers (unless Company appoints others)	Immediately after Closing	Integration of target company management
Board of Directors of Purchaser (post-Closing)	Current Purchaser directors	Seven individuals: two designated by Company (not necessarily independent), one nominated by Parent (acceptable to Company, not necessarily independent), and four designated by Company (acceptable to Parent, independent, one audit committee financial expert)	As of Closing	Formation of new combined entity board
Directors and Officers of Company	Current Company directors and officers	NA (resignations requested by Purchaser)	As of Closing	Transition to wholly-owned subsidiary status and new board structure for Purchaser

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Organizational Documents Amendment	The Certificate of Incorporation and Bylaws of Purchaser will be amended and restated.	Redomestication Merger Effective Time	Establishes the governing framework for the publicly traded combined entity.
Equity Incentive Plan Adoption	A new equity incentive plan will be adopted, reserving 15% of the aggregate Purchaser Common Stock immediately after the Closing for awards.	As of Closing	Provides a mechanism for attracting, retaining, and incentivizing employees and directors of the combined company.
Board Composition	The post-Closing Purchaser Board of Directors will consist of seven individuals, including independent directors and an audit committee financial expert, as designated by the Company and Parent.	As of Closing	Establishes the leadership and oversight structure for the combined public company, aligning with Nasdaq listing requirements.
Audit Committee Establishment	Purchaser will establish an audit committee with at least three independent directors within 90 days of Nasdaq listing, including one audit committee financial expert.	Within 90 days of Nasdaq listing	Ensures compliance with Nasdaq corporate governance rules and enhances financial oversight.
Stockholders Agreement Termination	The existing Stockholders Agreement of the Company, dated September 17, 2024, will be terminated.	As of Closing	Simplifies the governance structure of PrimeGen as it becomes a wholly-owned subsidiary.
Lock-up Agreements	Lock-up agreements will be executed by the Sponsor, certain Company stockholders, and Company directors/officers, restricting transfers of shares for 180 days post-closing or until certain price/liquidation events.	Effective Time of Business Combination	Aims to stabilize the stock price post-merger by limiting immediate selling pressure from key stakeholders.
Registration Rights Agreement	A Registration Rights Agreement will be entered into at Closing, providing registration rights to certain Company stockholders and the Sponsor.	As of Closing	Facilitates future liquidity for key shareholders by allowing them to register and sell their shares under certain conditions.

Legal Proceedings

No specific legal proceedings are currently pending or threatened against the Company or Parent Parties, beyond general risks associated with litigation mentioned in forward-looking statements.

Related Party Transactions

Significant Company Holders (including directors and Stem Med Scientific, Inc.) have entered into a Company Support Agreement to vote in favor of the merger.
The Sponsor and Parent's directors/officers have entered into an Insider Support Agreement, agreeing to vote in favor of the merger and not to redeem their shares.
The Sponsor will receive a $2,500,000 payment at Closing in exchange for 250,000 shares of Purchaser Common Stock.
Parent Transaction Expenses may include loans owed by Parent to the Sponsor.
The PG License Agreement between PrimeGen Biotech LLC and PrimeGen US, Inc. will be amended to restrict voluntary transfer of material Licensed Patents by PrimeGen Biotech LLC without PrimeGen US, Inc.'s written consent.

Stakeholder Impact

Shareholders of DTCS will vote on the merger, have redemption rights, and will receive Purchaser Class A Common Stock and potentially Non-Redemption Warrants, transitioning their investment from a SPAC to a biotechnology operating company.
Shareholders of PrimeGen will exchange their Company shares for Purchaser Class A or Class B Common Stock, becoming shareholders in the new public entity, subject to lock-up restrictions.
Key management and employees of PrimeGen are expected to continue in their roles within the Surviving Corporation and the new public entity, benefiting from a new equity incentive plan designed for retention and incentive.
The Sponsor receives a cash payment, Non-Redemption Warrants, and potential repayment of expenses, while being subject to lock-up and registration rights for its shares.
Creditors, such as East West Bank for the Revolving Line of Credit Loan, will have their existing indebtedness managed by the Surviving Corporation.

Next Steps

Parent will prepare and file a Form S-4 registration statement (including a proxy statement) with the SEC.
Parent will solicit proxies from its shareholders and call an Extraordinary General Meeting (Parent EGM) to vote on the Parent Proposals, including the merger.
The Company will obtain the Required Company Stockholder Approval via written consent within ten days of the Registration Statement's effective date.
Purchaser Class A Common Stock issued as merger consideration must be approved for listing on Nasdaq.
The Redomestication Merger and Acquisition Merger will be consummated after all conditions are met or waived.
Purchaser will enter into a registration rights agreement with certain Company stockholders and the Sponsor at Closing.
Purchaser will issue Non-Redemption Warrants at the Redomestication Merger Effective Time.
The Sponsor will receive a $2,500,000 payment in exchange for 250,000 shares of Purchaser Common Stock at Closing.
Parent and Company Transaction Expenses will be paid at Closing.
The Company will deliver audited financial statements for fiscal year 2025 and timely deliver 2026 financial statements.

Key Dates

Date	Description
2024-07-24	Date of Insider Letter Agreements and Parent's initial public offering (IPO) prospectus.
2024-07-26	Date Parent's IPO prospectus was filed with the SEC.
2024-08-26	Approximate date of Company's reverse stock split.
2025-01-13	Date of Engagement Letter with CTM Advisory Limited (Corporate Advisor).
2025-02-12	Date of M&A Advisory Agreement with A.G.P./Alliance Global Partners, LLC (Financial Advisor).
2025-04-16	Date of Confidentiality Agreement between Parent and Company.
2025-09-30	Interim Balance Sheet Date for Company's unaudited financial statements.
2026-01-06	Date of Revolving Line of Credit Loan between East West Bank and Company.
2026-01-27	Trust Account balance reported as $17,951,466.48.
2026-01-29	Parent Ordinary Shares issued and outstanding reported as 3,419,314.
2026-02-02	Date of Business Combination Agreement.
2026-02-06	Date of Form 8-K filing.
2026-10-26	Outside Date for closing the Business Combination, subject to a possible three-month extension.

Keywords

SPAC, biotechnology, stem cell therapy, merger, acquisition, PrimeGen US, DT Cloud Star, SEC filing, corporate governance, Nasdaq listing, cell therapy, IND application, PGSXC-L1A, Acute Alcoholic Hepatitis, de-SPAC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.